skip to navigation skip to content
 

Accelerate Plus

These ventures have been with Accelerate Cambridge for over six months and are looking at raising their seed round.

Anvil

 Anvil is a tool that takes the pain out of software development, without sacrificing power. Companies are best placed to know their own businesses and develop their own business process tools, but developing web applications is hugely slow and complicated. Anvil's visual designer, simple Python code environment and "batteries-included" philosophy makes business application development faster, easier and more agile.

Visit the Anvil website

Anvil logo

Capito Systems

Capito Systems (est. 2012), also trading as capito.ai, specialises in the contextual understanding of natural language (NLU). We have built a high performance NLU cloud platform that delivers application-specific semantic understanding of free-form voice and text inputs at speed and scale. Applications include intelligent voice control, conversational interfaces like chat bots, and semantic search. Our technology is platform-independent and easy to integrate via our APIs. We are able to ‘bootstrap’ NLU models quickly using the latest machine learning techniques coupled with our streamlined development workflows in support of rapid prototyping & testing. Unlike other NLP/NLU solutions, including the “open developer platforms” offered by major players like Amazon, Microsoft and Facebook, ours is a premium NLU product customised for each use case by our in-house experts, as we seek to develop long-term relationships with our clients.

Visit the Capito Systems website

Capito.ai logo

cThings

cThings Limited is an IoT solution provider specifically developing products for social housing, elderly care and the private rental markets. Our products enable landlords and carers to have complete visibility of their properties and their associated assets to ensure the best quality of service for their residents.

cThings has developed a truly revolutionary suite of modular hardware which enables our clients to monitor, control and engage with their properties in real time. The flexibility of our hardware enables cThings to adapt its product set to meet specific customers requirements with minimal time and expense.

Combining our innovative hardware with event-based alerts and data analytics from the cThings cloud provides customers with valuable insights, allowing them to reduce costs, provide an improved resident experience and safe guard vulnerable residents.

cThings enables our customers to provide better and safer homes through technology.

cThings logo

LIFNanoRx

LIFNanoRx is a nano-bio-med company focused on treatment of Multiple Sclerosis (MS), a disabling incurable auto-immune inflammatory disease of the central nervous system (CNS) commonly affecting young adults. LIF - short for Leukaemia Inhibitory Factor - is a critical stem cell factor that has unique biological properties: these not only promote tissue repair but also suppress disease-linked inflammation. These therapeutic properties are harnessed in LIFNanoRx's targeted medicinal nanoparticle - "LIFNano" - providing a safe, cell-free, drug-free and potentially curative approach to MS. The technology is patented and LIFNanoRx holds worldwide exclusive licence in exploitation of LIF using their NanoMed platform technology.

LIFNanoRx logo

PHARMeNABLE

PharmEnable supports early drug-discovery programs by providing a rapid, cost-efficient and effective platform to identify new chemical starting points for drug development.

Visit the PHARMeNABLE website

Pharmenable logo

Satavia

 Satavia is an analytics and visualisation company that develops bespoke environmental awareness solutions for all segments of the aviation market. We aim to provide ‘personalised environmental health management’ for aircraft and unmanned aerial systems to reinforce the safety and reliability of flight operations, while minimising unanticipated maintenance costs. Satavia delivers live aircraft-centric metrics for a range of environmental threats and combines expertise in aeronautical meteorology, big data and analytics, and 3-D visualisation technology.

Satavia logo

Solidi

Digital currencies represent the future of global on and offline payments. They are fast, cheap, convenient, irreversible and do not rely on a central authority to oversee and run them. They are not limited by geography or nationality and enable payments to be made between people on opposite sides of the globe in seconds lowering the barrier to global business and travel. At the same time, their design and cost structure enable the 2.5 billion unbanked adults worldwide (over 60 per cent of the world's adult population) to finally have a method of transacting and saving out with the cash economy. 

Solidi aims to make buying, selling, spending and holding digital currencies as easy as using cash, while retaining all the benefits of an unforgeable digital token. 

We provide a UK-based, person-to-person matching exchange tightly integrated with the UK Faster Payments System, a mobile app to buy and sell on the exchange, monthly savings options, and an easy to use mobile wallet which supports repurchasing digital currencies as you spend them. 

We are regulated by HMRC as a Bureau de Change and are actively pursuing registration with the FCA as a Money Services Business. Our founders have substantial experience in FinTech and mobile having worked at major investment banks and mobile technology firms.

contact@solidi.co

Visit the Solidi website

Solidi logo

SPIREA

SPIREA is a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

The technology is based on biodegradable polymeric formulations of a combination of drugs for targeted and sustained release that will ultimately improve the efficacy and safety of treatments and patient compliance and comfort. This means a simpler, safer and more effective treatment for various diseases and a pioneering strategy in the management of diseases by combination therapy.

SPIREA aims to establish the polymer platform as a major player in the drug delivery space by partnering with pharmaceutical and biotech companies.

SPIREA logo

Swift Molecular Diagnostics

Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.

We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.

Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips

SwiftDX